bioRxivMicrobiology
High-Throughput Human Primary Cell-Based Airway Model for Evaluating Influenza, Coronavirus, or other Respiratory Viruses in vitro
A. L. Gard, R. Maloney, B. P. Cain, C. R. Miller, R. J. Luu, J. R. Coppeta, P. Liu, J. P. Wang, H. Azizgolshani, R. F. Fezzie, J. L. Balestrini, B. C. Isenberg, R. W. Finberg, J. T. Borenstein
Abstract
Influenza and other respiratory viruses represent a significant threat to public health, national security, and the world economy, and can lead to the emergence of global pandemics such as the current COVID-19 crisis. One of the greatest barriers to the development of effective therapeutic agents to treat influenza, coronaviruses, and many other infections of the respiratory tract is the absence of a robust preclinical model. Preclinical studies currently rely on high-throughput, low-fidelity in vitro screening with cell lines and/or low-throughput animal models that often provide a poor correlation to human clinical responses. Here, we introduce a human primary airway epithelial cell-based model integrated into a high-throughput platform where tissues are cultured at an air-liquid interface (PREDICT96-ALI). We present results on the application of this platform to influenza and coronavirus infections, providing multiple readouts capable of evaluating viral infection kinetics and potentially the efficacy of therapeutic agents in an in vitro system. Several strains of influenza A virus are shown to successfully infect the human primary cell-based airway tissue cultured at an air-liquid interface (ALI), and as a proof-of-concept, the effect of the antiviral oseltamivir on one strain of Influenza A is evaluated. Human coronaviruses NL63 (HCoV-NL63) and SARS-CoV-2 enter host cells via ACE2 and utilize the protease TMPRSS2 for protein priming, and we confirm expression of both in our ALI model. We also demonstrate coronavirus infection in this system with HCoV-NL63, observing sufficient viral propagation over 96 hours post-infection to indicate successful infection of the primary cell-based model. This new capability has the potential to address a gap in the rapid assessment of therapeutic efficacy of various small molecules and antiviral agents against influenza and other respiratory viruses including coronaviruses.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents
H. Zarkoob, A. Allue-Guardia, … E. M. Lee·bioRxiv·May 11, 2021
- A novel, anatomy-similar in vitro model of 3D airway epithelial for anti-coronavirus drug discovery
- SARS-CoV-2 Viral Replication in a High Throughput Human Primary Epithelial Airway Organ Model
C. R. Fisher, F. M. Medie, … A. L. Gard·bioRxiv·Jun 15, 2021
- A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
T. N. D. Do, K. Donckers, … D. Jochmans·bioRxiv·Mar 25, 2021
- Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform
C. R. Fisher, F. M. Medie, … A. L. Gard·bioRxiv·Jun 7, 2022
- A human primary airway microphysiological system infected with SARS-CoV-2 distinguishes the treatment efficacy between nirmatrelvir and repurposed compounds fluvoxamine and amodiaquine
L. Lopez Quezada, F. Mba Medie, … A. L. Gard·bioRxiv·Jun 27, 2023